TD Asset Management
SMMT icon

TD Asset Management’s Summit Therapeutics SMMT Stock Holding History

TD Asset Management’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.21M Sell
426,084
-530,810
-55% -$9.41M 0.01% 769
2026
Q1 		$18.1M Sell
956,894
-248,378
-21% -$4.02M 0.01% 531
2025
Q4 		$21.1M Buy
1,205,272
+667,742
+124% +$12.6M 0.02% 500
2025
Q3 		$11.1M Buy
537,530
+53,520
+11% +$1.3M 0.01% 634
2025
Q2 		$10.3M Sell
484,010
-323,180
-40% -$7.37M 0.01% 631
2025
Q1 		$15.6M Sell
807,190
-30,764
-4% -$617K 0.01% 547
2024
Q4 		$15M Buy
837,954
+143,232
+21% +$2.78M 0.01% 561
2024
Q3 		$14.5M Buy
694,722
+427,922
+160% +$5.98M 0.01% 573
2024
Q2 		$2.08M Buy
+266,800
New +$1.44M ﹤0.01% 992

Other funds holding SMMT

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

TD Asset Management's SMMT Position: Q2 2026 in Review

TD Asset Management reduced its Summit Therapeutics (SMMT) stake by 55% in Q2 2026, selling an estimated $9.41M and leaving 426,084 shares worth $6.21M. The position accounts for 0.01% of the portfolio, ranked #769.

TD Asset Management first reported a position in SMMT in Q2 2024 and has held it in 9 quarters since. The position peaked at $21.1M in Q4 2025. 155 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • TD Asset Management held 426,084 shares of Summit Therapeutics worth $6.21M as of Q2 2026.
  • TD Asset Management sold 530,810 Summit Therapeutics shares in Q2 2026, an estimated $9.41M.
  • Summit Therapeutics made up 0.01% of TD Asset Management's portfolio in Q2 2026, its #769 holding.
  • TD Asset Management first reported a position in Summit Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • TD Asset Management's Summit Therapeutics position peaked at $21.1M in Q4 2025.
  • 155 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on TD Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.